期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

磷酸二酯酶5抑制剂治疗先天性心脏病合并肺动脉高压 被引量：1

Phosphodiesterase 5 inhibitors treatment of congenital heart disease with pulmonary arterial hypertension
原文传递
导出
摘要 肺动脉高压在先天性心脏病中很常见，有效地降低患儿肺血管阻力，能够改善其远期生存率。对肺动脉高压病理生理的研究发现，使用磷酸二酯酶5抑制剂可使肺血管舒张，降低肺血管阻力。目前磷酸二酯酶5抑制剂西地那非在国外已用于治疗肺动脉高压。多个临床试验已经证明磷酸二酯酶5抑制剂能够显著降低肺血管阻力，改善患者远期生存率和生活质量，且能较好地被患者耐受。 Pulmonary arterial hypertension is conanon in patients with congenital heart disease. An effective reduction in pulmonary vascular resistance could improve the survival rate in the future. Research in the pathophysiology of pulmonary arterial hypertension shows that phosphodiesterase 5 inhibitors result in pulmonary vasodilation, decrease vascular resistance. Sildenafil, a inhibitor of phosphediesterase 5 has been permitted to treat pulmonary arterial hypertension oversea now. Phosphediesterase 5 inhibitors are proved to reduce pulmonary vascular resistance significantly, improve the survival rate in the future and be well tolerated. This review contains the changes of bemedynamics, exercise tolerance, side effect and pharmacokinetics of phosphodiesterase 5 inhibitors.
作者 龚霄雷(综述) 徐卓明 刘锦纷(审校)
机构地区 上海交通大学医学院附属上海儿童医学中心心胸外科
出处 《国际儿科学杂志》 2010年第2期142-144,185,共4页 International Journal of Pediatrics
关键词 磷酸二酯酶5抑制剂 肺动脉高压 先天性心脏病 Phosphodiesterase 5 inhibitors Pulmonary arterial hypertension Congenital heart disease
分类号 R983 [医药卫生—药品]
  • 相关文献

二级参考文献257

  • 1Omori K, KoteraJ. Overview of PDEs and their regulation. Circ Res 2007; 100: 309-27.
  • 2Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007; 100: 489-501.
  • 3Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58: 488-520.
  • 4Osadchii OE. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc Drugs Ther 2007; 21: 171-94.
  • 5Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007; 99:4A-23A.
  • 6Wang S, Cone J, Fong M, Yoshitake M, Kambayashi J, Liu Y. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol2001; 38: 775-83.
  • 7Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Hernandez M, et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind doubledummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 1988; 238: 2-6.
  • 8Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007; 144: 239-46.
  • 9Calverley PM, Sanchez-Toril F, Mclvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. AmJ Respir Crit Care Med 2007; 176: 154-61.
  • 10Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5: 689-702.

共引文献5

同被引文献50

  • 1Nold-Petry CA, Rudloff I,Baumer Y,et al. IL-32 promotes angiogen-esis[ J]. J Immunol,2014,192(2) :589-602. DOI: 10. 4049/jimmu-nol. 1202802.
  • 2Jiang Y,Nohe A, Bragdon B,et al. Trapping of BMP receptors indistinct membrane domains inhibits their function in pulmonary arte-rial hypertension [ J ]. Am J Physiol Lung Cell Mol Physiol,2011,301(2) : L218-227. DOI: http://dx. DOI. org/10. 1152/ajplung.00300.2010.
  • 3Zhao M,Austin ED,Hemnes AR,et al. An evidence-based knowl-edgebase of pulmonary arterial hypertension to identify genes andpathways relevant to pathogenesis[ J]. Mol Biosyst,2014,10(4):732-740. DOI: 0.1039/c3mb70496c.
  • 4Van Wijk B,Moorman AF, Van Den Hoff MJ. Role of bone mor-phogenetic proteins in cardiac differentiation [ J]. Cardiovasc Res,2007,74(2) :244-255. DOI: 10.1016/j. cardiores. 2006.11.022.
  • 5Kishigami S,Mishina Y. BMP signaling and early embryonic pat-terning [J]. Cytokine Growth Factor Rev, 2005,16 (3) : 265-278.DOI: 10.1016/j. cytogfr. 2005.04.002.
  • 6Miyazono K,Kamiya Y,Morikawa M. Bone morphogenetic proteinreceptors and signal transduction[ J]. J Biochem,2010,147 (1):35-51. DOI: 10.1093/jb/mvpl48.
  • 7Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bonemorphogenetic protein receptor-2 signaling promotes pulmonary arte-rial endothelial cell survival : implications for loss-of-function muta-tions in the pathogenesis of pulmonary hypertension [ J ]. Circ Res,2006,98(2) :209-217.D01:10.1161/01.RES.0000200180.01710.e6.
  • 8Wei ZQ,Salmon RM,Upton PD,et al. Regulation of bone morpho-genetic protein 9(BMP9)by redox-dependent proteolysis[ J]. J BiolChem,2014,289 (45 ) : 31150-31159. DOI: 10. 1074/jbc. Ml 14.579771.
  • 9Lafyatis R. Transforming growth factor beta~at the centre of system-ic sclerosis[ J]. Nat Rev Rheumatol,2014,10(12) :706-719. DOI:10.1038/nrrheum. 2014.137.
  • 10Zhang YE. Non-Smad pathways in TGF-beta signaling [ J]. CellRes,2009,19(1) :128-139.DOI:10.1038/cr.2008.328.

引证文献1

二级引证文献2

国际儿科学杂志
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部